Assessment Following Total Neoadjuvant Therapy for Rectal Cancer
Authors:
Open Access
- 7 January 2026
- journal article
- review article
- Published by Georg Thieme Verlag KG in Clinics in Colon and Rectal Surgery
Abstract
Over the past decade, total neoadjuvant therapy (TNT) has become increasingly accepted and adopted as the initial treatment for locally advanced rectal cancer. Following TNT, treatment response is assessed using three main modalities: clinical exam, endoscopy, and imaging. In this article, we summarize the known advantages, disadvantages, and controversies associated with each method of assessment.Keywords
This publication has 36 references indexed in Scilit:
- Rectal cancer lexicon 2023 revised and updated consensus statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused PanelAbdominal Radiology, 2023
- A primer on rectal MRI in patients on watch-and-wait treatment for rectal cancerAbdominal Radiology, 2023
- Diagnostic performance of magnetic resonance to assess treatment response after neoadjuvant therapy in patients with locally advanced rectal cancerAbdominal Radiology, 2019
- Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal CancerJAMA Oncology, 2018
- Clinical relevance of morphologic MRI criteria for the assessment of lymph nodes in patients with rectal cancerInternational Journal of Colorectal Disease, 2015
- Endoscopic evaluation of clinical response after preoperative chemoradiotherapy for lower rectal cancer: the significance of endoscopic complete responseInternational Journal of Colorectal Disease, 2015
- Optimal Timing for Assessment of Tumor Response to Neoadjuvant Chemoradiation in Patients With Rectal Cancer: Do All Patients Benefit From Waiting Longer Than 6 Weeks?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Diffusion‐weighted Magnetic Resonance Imaging for Detecting Lymph Node Metastasis of Rectal CancerWorld Journal of Surgery, 2011
- Low rectal cancerDiseases of the Colon & Rectum, 1998
- Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlationsCancer, 1994